Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13

Zuzana Tobiasova, Klaas H B Van Der Lingen, Lawrence Scahill, James F. Leckman, Yan Zhang, Wookjin Chae, James T. McCracken, Christopher J. McDougle, Benedetto Vitiello, Elaine Tierney, Michael G. Aman, L. Eugene Arnold, Liliya Katsovich, Pieter J. Hoekstra, Fred Volkmar, Alfred L M Bothwell, Ivana Kawikova

Research output: Contribution to journalArticle

Abstract

Risperidone has been shown to improve serious behavioral problems in children with autism. Here we asked whether risperidone-associated improvement was related to changes in concentrations of inflammatory molecules in the serum of these subjects. Seven molecules were identified as worthy of further assessment by performing a pilot analysis of 31 inflammatory markers in 21 medication-free subjects with autism versus 15 healthy controls: epidermal growth factor (EGF), interferon-γ (IFN-γ), interleukin (IL)-13, IL-17, monocyte chemoattractant protein-1 (MCP-1), IL-1 and IL-1-receptor antagonist. Serum concentrations of these markers were then established in a different set of subjects that participated in a double-blind, clinical trial and an expanded group of healthy subjects. In the first analysis, samples obtained from subjects with autism at baseline visits were compared to visits after 8-week treatment with placebo (n=37) or risperidone (n=40). The cytokine concentrations remained stable over the 8-week period for both risperidone and placebo groups. In the second analysis, we explored further the differences between medication-free subjects with autism (n=77) and healthy controls (recruited independently; n=19). Serum levels of EGF were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p

Original languageEnglish (US)
Pages (from-to)555-564
Number of pages10
JournalJournal of Child and Adolescent Psychopharmacology
Volume21
Issue number6
DOIs
StatePublished - Dec 1 2011

Fingerprint

Risperidone
Interleukin-13
Autistic Disorder
Epidermal Growth Factor
Serum
Placebos
Interleukin-1 Receptors
Interleukin-17
Chemokine CCL2
Interleukin-1
Interferons
Healthy Volunteers
Biomarkers
Clinical Trials
Cytokines

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13. / Tobiasova, Zuzana; Van Der Lingen, Klaas H B; Scahill, Lawrence; Leckman, James F.; Zhang, Yan; Chae, Wookjin; McCracken, James T.; McDougle, Christopher J.; Vitiello, Benedetto; Tierney, Elaine; Aman, Michael G.; Arnold, L. Eugene; Katsovich, Liliya; Hoekstra, Pieter J.; Volkmar, Fred; Bothwell, Alfred L M; Kawikova, Ivana.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 21, No. 6, 01.12.2011, p. 555-564.

Research output: Contribution to journalArticle

Tobiasova, Z, Van Der Lingen, KHB, Scahill, L, Leckman, JF, Zhang, Y, Chae, W, McCracken, JT, McDougle, CJ, Vitiello, B, Tierney, E, Aman, MG, Arnold, LE, Katsovich, L, Hoekstra, PJ, Volkmar, F, Bothwell, ALM & Kawikova, I 2011, 'Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13', Journal of Child and Adolescent Psychopharmacology, vol. 21, no. 6, pp. 555-564. https://doi.org/10.1089/cap.2010.0134
Tobiasova, Zuzana ; Van Der Lingen, Klaas H B ; Scahill, Lawrence ; Leckman, James F. ; Zhang, Yan ; Chae, Wookjin ; McCracken, James T. ; McDougle, Christopher J. ; Vitiello, Benedetto ; Tierney, Elaine ; Aman, Michael G. ; Arnold, L. Eugene ; Katsovich, Liliya ; Hoekstra, Pieter J. ; Volkmar, Fred ; Bothwell, Alfred L M ; Kawikova, Ivana. / Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13. In: Journal of Child and Adolescent Psychopharmacology. 2011 ; Vol. 21, No. 6. pp. 555-564.
@article{b6dd93ff63d64e5e8122255ca81ac6ac,
title = "Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13",
abstract = "Risperidone has been shown to improve serious behavioral problems in children with autism. Here we asked whether risperidone-associated improvement was related to changes in concentrations of inflammatory molecules in the serum of these subjects. Seven molecules were identified as worthy of further assessment by performing a pilot analysis of 31 inflammatory markers in 21 medication-free subjects with autism versus 15 healthy controls: epidermal growth factor (EGF), interferon-γ (IFN-γ), interleukin (IL)-13, IL-17, monocyte chemoattractant protein-1 (MCP-1), IL-1 and IL-1-receptor antagonist. Serum concentrations of these markers were then established in a different set of subjects that participated in a double-blind, clinical trial and an expanded group of healthy subjects. In the first analysis, samples obtained from subjects with autism at baseline visits were compared to visits after 8-week treatment with placebo (n=37) or risperidone (n=40). The cytokine concentrations remained stable over the 8-week period for both risperidone and placebo groups. In the second analysis, we explored further the differences between medication-free subjects with autism (n=77) and healthy controls (recruited independently; n=19). Serum levels of EGF were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p",
author = "Zuzana Tobiasova and {Van Der Lingen}, {Klaas H B} and Lawrence Scahill and Leckman, {James F.} and Yan Zhang and Wookjin Chae and McCracken, {James T.} and McDougle, {Christopher J.} and Benedetto Vitiello and Elaine Tierney and Aman, {Michael G.} and Arnold, {L. Eugene} and Liliya Katsovich and Hoekstra, {Pieter J.} and Fred Volkmar and Bothwell, {Alfred L M} and Ivana Kawikova",
year = "2011",
month = "12",
day = "1",
doi = "10.1089/cap.2010.0134",
language = "English (US)",
volume = "21",
pages = "555--564",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13

AU - Tobiasova, Zuzana

AU - Van Der Lingen, Klaas H B

AU - Scahill, Lawrence

AU - Leckman, James F.

AU - Zhang, Yan

AU - Chae, Wookjin

AU - McCracken, James T.

AU - McDougle, Christopher J.

AU - Vitiello, Benedetto

AU - Tierney, Elaine

AU - Aman, Michael G.

AU - Arnold, L. Eugene

AU - Katsovich, Liliya

AU - Hoekstra, Pieter J.

AU - Volkmar, Fred

AU - Bothwell, Alfred L M

AU - Kawikova, Ivana

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Risperidone has been shown to improve serious behavioral problems in children with autism. Here we asked whether risperidone-associated improvement was related to changes in concentrations of inflammatory molecules in the serum of these subjects. Seven molecules were identified as worthy of further assessment by performing a pilot analysis of 31 inflammatory markers in 21 medication-free subjects with autism versus 15 healthy controls: epidermal growth factor (EGF), interferon-γ (IFN-γ), interleukin (IL)-13, IL-17, monocyte chemoattractant protein-1 (MCP-1), IL-1 and IL-1-receptor antagonist. Serum concentrations of these markers were then established in a different set of subjects that participated in a double-blind, clinical trial and an expanded group of healthy subjects. In the first analysis, samples obtained from subjects with autism at baseline visits were compared to visits after 8-week treatment with placebo (n=37) or risperidone (n=40). The cytokine concentrations remained stable over the 8-week period for both risperidone and placebo groups. In the second analysis, we explored further the differences between medication-free subjects with autism (n=77) and healthy controls (recruited independently; n=19). Serum levels of EGF were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p

AB - Risperidone has been shown to improve serious behavioral problems in children with autism. Here we asked whether risperidone-associated improvement was related to changes in concentrations of inflammatory molecules in the serum of these subjects. Seven molecules were identified as worthy of further assessment by performing a pilot analysis of 31 inflammatory markers in 21 medication-free subjects with autism versus 15 healthy controls: epidermal growth factor (EGF), interferon-γ (IFN-γ), interleukin (IL)-13, IL-17, monocyte chemoattractant protein-1 (MCP-1), IL-1 and IL-1-receptor antagonist. Serum concentrations of these markers were then established in a different set of subjects that participated in a double-blind, clinical trial and an expanded group of healthy subjects. In the first analysis, samples obtained from subjects with autism at baseline visits were compared to visits after 8-week treatment with placebo (n=37) or risperidone (n=40). The cytokine concentrations remained stable over the 8-week period for both risperidone and placebo groups. In the second analysis, we explored further the differences between medication-free subjects with autism (n=77) and healthy controls (recruited independently; n=19). Serum levels of EGF were elevated in subjects with autism (median=103 pg/mL, n=75) in comparison to healthy controls (75 pg/mL, n=19; p

UR - http://www.scopus.com/inward/record.url?scp=84555189942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84555189942&partnerID=8YFLogxK

U2 - 10.1089/cap.2010.0134

DO - 10.1089/cap.2010.0134

M3 - Article

C2 - 22070180

AN - SCOPUS:84555189942

VL - 21

SP - 555

EP - 564

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 6

ER -